| Name | AZD-1305 |
| Description | AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias. |
| In vitro | AZD1305 (0.1–30 µM, n = 6, each concentration applied for 3 min ; dog cardiomyocytes) concentration-dependently blocked INalate (IC50=4.3 microM) and INapeak (IC50=66 microM). In PFs, E-4031, but not AZD1305, markedly prolonged APD90 (from 380+/-15 to 597+/-86 ms, P<0.05) after the long CL and augmented APD90 instability (2+/-0.4 to 24+/-6.1 ms, P<0.05), increases significantly attenuated by AZD1305 and lidocaine.[3] |
| In vivo | AZD1305 ((36g/kg/min intravenously for 30 minutes ; anesthetized mongrel dogs) respectively increased QT and RR intervals from 290±7 to 397±15 ms (+37%, P<0.0001) and from 603±22 to 778±32 ms (+29%, P=0.002) at normal sinus rhythm. AZD1305 increased the QT interval from 535±28 to 747±36 ms (+40%, P<0.0001). AZD1305 slightly slowed the idioventricular rhythm.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (57.54 mM), Sonication is recommended.
|
| Keywords | AZD-1305 | AZD1305 |
| Inhibitors Related | Quadrol | 2,4,6-Tri-tert-butylphenol | Phenytoin sodium | Chlorocresol | L-Ascorbic acid | 1,8-Cineole | Valproic Acid | Chenodeoxycholic acid | L-Ascorbic acid sodium salt | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Magnesium sulfate |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Calcium Channel Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
